| Autor: |
Ananta, Swati Banerjee, Paul B. Tchounwou, Sanjay Kumar |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Current Research in Pharmacology and Drug Discovery, Vol 5, Iss , Pp 100166- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2590-2571 |
| DOI: |
10.1016/j.crphar.2023.100166 |
| Popis: |
Acute promyelocytic leukemia (APL) /blood cancer is a M3 type of acute myeloid leukemia (AML) that is formed inside bone marrow as result of a chromosomal translocation mutation between chromosomes 15 and 17. It accounts for about 10% cases of AML worldwide. Trisenox (TX) is used in chemotherapy for the treatment of all age groups of APL patients, showing the highest efficacy and survival rate for a considerable time-period. High concentration of TX inhibits the growth of APL cells by diverse mechanisms. However, it is effective only on APL patients who have the PML-RARα fusion gene/oncogene. TX resistance has been reported worldwide for APL patients who have a different oncogenic make-up. This review summarizes the updated mechanisms of TX action via PML nuclear bodies formation, proteasomal degradation, autophagy, p53 activation, telomerase activity, heteromerization of pRb & E2F, and regulation of signaling mechanisms in APL cells. We have also provided important information on the molecular mechanisms of action of the combination therapy of TX and other drugs in acute leukemia cells. Taken together, this review highlights the new modes of action of TX action, and provides valuable information for finding new targets and advancing research in APL pathophysiology or designing new drugs for the treatment of TX-resistant APL patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
